This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Syndax Pharmaceuticals, Inc.
Drug Names(s): SNDX-275, MS-275, KHK2375
Description: Entinostat (SNDX-275) is an oral class I–selective HDAC inhibitor. HDAC2 inhibitors are members of a class of agents that modulate the expression of genes by causing an increase in histone acetylation, thereby regulating chromatin structure and transcription.
Syndax and Bayer
In April 2007, Syndax acquired worldwide development and commercial rights to entinostat (SNDX-275) (formerly MS-275) from Bayer Schering Pharma AG.
Syndax and Ventana Medical Systems
In January 2012, Syndax Pharmaceuticals and Ventana Medical Systems announced that the companies entered into an agreement to develop a companion diagnostic assay to select patients with non-small cell lung cancer (NSCLC) for treatment with erlotinib and entinostat. The assay is designed to identify patients with lung cancer patients with high levels of E-cadherin.
Syndax and Eddingpharm
In September 2013, Syndax and Eddingpharm entered into a licensing, development and commercialization agreement that gives Eddingpharm exclusive rights to develop, market, and sell entinostat in China, Hong Kong, Thailand, Macau, Taiwan, Malaysia and Singapore.
Syndax and Kyowa Hakko Kirin
In January 2015, Kyowa Hakko Kirin and Syndax...See full deal structure in Biomedtracker
Partners: Eddingpharm Kyowa Hakko Kirin Co., Ltd.
Additional information available to subscribers only: